Cancer Articles
The U.S. Food and Drug Administration has approved Erleada (apalutamide) to treat men with prostate cancer that has not yet spread but has a quickly rising PSA level while on treatment with hormone therapy, which causes concern for cancer growth and spread.
The U.S. Food and Drug Administration approved Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), the first biosimilar drug to treat cancer.
A nationwide epidemiological study showed cancer patients who continuously used disulfiram (Antabuse), a drug prescribed to alcoholics to prevent them from drinking, have a lower risk of death from cancer compared to those who stopped using the drug once diagnosed.
The U.S. Food and Drug Administration has approved Agios Pharmaceuticals’ Idhifa (enasidenib) to treat acute myelogenous leukemia.
Novartis’ Kymriah (tisagenlecleucel) has been approved by the U.S. Food and Drug Administration to treat pediatric acute lymphoblastic leukemia.
Researchers at the Moffitt Cancer Center are developing a new vaccine that will help early-stage breast cancer patients who have HER2 positive disease.
The Advisory Committee on Immunization Practices has changed its recommendation for the human papilloma virus from three doses to two doses of the vaccine prior to age 15.
The U.S. Department of Health andHuman Services has selected nearly 200 physician group practices and 17health insurance companies to participate in a care delivery model that supports and encourages higher quality and more coordinated cancer care.
A lung cancer vaccine developed in Cuba has been approved by the U.S. Food and Drug Administration for a clinical trial at Roswell Park Cancer Institute in Buffalo, N.Y.
Scientists at Yale have uncovered a molecular mechanism that causes variants in a specific immune response gene known as MIF (macrophage migration inhibitory factor).
Scientists from Harvard, MIT and University College London have made a discovery about the genetics of cancer tumors that could offer a new way to deliver customized immunotherapy drugs to kill all types of cancer, including the most complex such as melanoma and lung cancer.
The U.S. Food and Drug Administration granted accelerated approval for pembrolizumab (Keytruda, Merck & Co.) for treatment of patients with advanced (metastatic)
non-small cell lung cancer.